Quale sarebbe il prezzo per Handa Pharmaceuticals, Inc. (6620)

Il prezzo per Handa Pharmaceuticals, Inc. (6620) è $2.95

Qual è la capitalizzazione di mercato per Handa Pharmaceuticals, Inc. (6620)

La capitalizzazione di mercato per Handa Pharmaceuticals, Inc. (6620) è $491.95M

Handa Pharmaceuticals, Inc. (6620) Margine Operativo

Handa Pharmaceuticals, Inc. operates as a specialized drug company, concentrating its efforts on creating and advancing new medications for diverse health issues across both the United States and China. The firm currently offers Quetiapine XR, a treatment for Schizophrenia, as well as Dexlansoprazole DR capsules. Beyond its existing portfolio, Handa is actively cultivating a robust pipeline of therapies. This includes their cutting-edge ONCORE drug delivery platform, engineered to boost patient adherence and improve the safety of tyrosine kinase inhibitor oncology drugs. Other significant projects encompass a 505(b)(2)NDA therapeutic agent, Tascenso ODT for managing multiple sclerosis, and the oncology candidates HND-033 and HND-027. Furthermore, the company's development initiatives feature HND-004, designed for diabetic patients; HND-032, intended to aid in smoking cessation; and HND-026, a gastrointestinal medication. Founded in 2014, Handa Pharmaceuticals, Inc. has its main corporate headquarters situated in Tainan City, Taiwan.

Anno	Margine Operativo	Cambia
Non abbastanza dati per le date fornite.

Anno

Margine Operativo

Cambia

Non abbastanza dati per le date fornite.

Azienda	Margine Operativo	Differenza del margine operativo	Il paese
MERCK Kommanditgesellschaft auf Aktien MER.SW	0.00%	-	DE
Merck KGaA MRK.DE	0.00%	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0.00%	-	JP
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	22.93%	-	IN
Galderma Group AG GALD.SW	0.00%	-	CH

Azienda

Margine Operativo

Differenza del margine operativo

Il paese